Programmed death-1 expression on CD4+ and CD8+ T cells in treated and untreated HIV disease

AIDS

Volumn 28, Issue 12, 2014, Pages 1749-1758

  Cockerham, Leslie R ^a   Jain, Vivek ^a   Sinclair, Elizabeth ^b   Glidden, David V ^c   Hartogenesis, Wendy ^a   Hatano, Hiroyu ^a   Hunt, Peter W ^a   Martin, Jeffrey N ^c   Pilcher, Christopher D ^a   Sekaly, Rafick ^d   McCune, Joseph M ^b   Hecht, Frederick M ^a   Deeks, Steven G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Division of Experimental Medicine   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Vaccine and Gene Therapy Institute of Florida   (United States)

Author keywords

early antiretroviral therapy; HIV antiretroviral therapy; HIV 1 immunology ; humans; physiology; programmed death 1; T lymphocytes immunology ; T cell activation; virus replication physiology

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HLA DR ANTIGEN; PROGRAMMED DEATH 1 RECEPTOR; VIRUS RNA; ANTIRETROVIRUS AGENT; PDCD1 PROTEIN, HUMAN;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; EARLY INTERVENTION; EFFECTOR CELL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; THERAPY DELAY; VIRUS LOAD; BLOOD; CHEMISTRY; COHORT ANALYSIS; HIV INFECTIONS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY;

ADULT; ANTI-RETROVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; PROSPECTIVE STUDIES; RNA, VIRAL; VIRAL LOAD;

EID: 84904176435     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000314     Document Type: Article

References (35)

1. Battegay M, Nuesch R, Hirschel B, Kaufmann GR. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis 2006 6280-287.
2. Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to 3.Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, et al.T cell activation is associated with lower CD4R T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy.J Infect Dis20031871534-1543
3. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, et al. T cell activation is associated with lower CD4R T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003 1871534-1543.
4. Cockerham L, Scherzer R, Zolopa A, Rimland D, Lewis CE, Bacchetti P, et al. Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era. J Acquir Immune Defic Syndr 2010 53102-106.
5. Lodwick RK, Sabin CA, Porter K, Ledergerber B, van Sighem A, Cozzi-Lepri A, et al. Death rates in HIV-positive antiretroviralnaive patients with CD4 count greater than 350 cells per microL in Europe and North America a pooled cohort observational study. Lancet 2010 376340-345.
6. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, et al. Upregulation of PD-1 expression on HIVspecific CD8R T cells leads to reversible immune dysfunction. Nat Med 2006 121198-1202.
7. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006 443350-354.
8. D'Souza M, Fontenot AP, Mack DG, Lozupone C, Dillon S, Meditz A, et al. Programmed death 1 expression on HIVspecific CD4R T cells is driven by viral replication and associated with T cell dysfunction. J Immunol 2007 1791979-1987.
9. Petrovas C, Price DA, Mattapallil J, Ambrozak DR, Geldmacher C, Cecchinato V, et al. SIV-specific CD8R T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection. Blood 2007 110928-936.
10. Dyavar Shetty R, Velu V, Titanji K, Bosinger SE, Freeman GJ, Silvestri G, et al. PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. J Clin Invest 2012 1221712-1716.
11. Breton G, Chomont N, Takata H, Fromentin R, Ahlers J, Filali-Mouhim A, et al. Programmed death-1 is a marker for abnormal distribution of naive/memory T cell subsets in HIV-1 infection. J Immunol 2013 1912194-2204.
12. Porichis F, Kwon DS, Zupkosky J, Tighe DP, McMullen A, Brockman MA, et al. Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood 2011 118965-974.
13. Amancha PK, Hong JJ, Rogers K, Ansari AA, Villinger F. In vivo blockade of the programmed cell death-1 pathway using soluble recombinant PD-1-Fc enhances CD4R and CD8R T cell responses but has limited clinical benefit. J Immunol 2013 1916060-6070.
14. Seung E, Dudek TE, Allen TM, Freeman GJ, Luster AD, Tager AM. PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads. PLoS One 2013 8e77780.
15. Velu V, Titanji K, Zhu B, Husain S, Pladevega A, Lai L, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009 458206-210.
16. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009 15893-900.
17. Hatano H, Jain V, Hunt PW, Lee TH, Sinclair E, Do TD, et al. Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4R T cells. Infect Dis 2013 20850-56.
18. Spitsin S, Tustin NB, Riedel E, Tustin R 3rd, Murray JB, Peck LM, et al. Programmed death 1 receptor changes ex vivo in HIVinfected adults following initiation of highly active antiretroviral therapy. Clin Vacc Immunol 2012 19752-756.
19. Grabmeier-Pfistershammer K, Steinberger P, Rieger A, Leitner J, Kohrgruber N. Identification of PD-1 as a unique marker for failing immune reconstitution in HIV-1-infected patients on treatment. J Acquir Immune Defic Syndr 2011 56118-124.
20. Piconi S, Trabattoni D, Gori A, Parisotto S, Magni C, Meraviglia P, et al. Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4R T-cell counts during antiretroviral therapy. AIDS 2010 241991-2000.
21. Conrad JA, Ramalingam RK, Duncan CB, Smith RM, Wei J, Barnett L, et al. Antiretroviral therapy reduces the magnitude and T cell receptor repertoire diversity of HIV-specific T cell responses without changing T cell clonotype dominance. J Virol 2012 864213-4221.
22. Nakanjako D, Ssewanyana I, Mayanja-Kizza H, Kiragga A, Colebunders R, Manabe YC, et al. High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort. BMC Infect Dis 2011 1143.
23. Jain V, Hartogensis W, Bacchetti P, Hunt PW, Hatano H, Sinclair E, et al. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis 2013 2081202-1211.
24. Kaplan RC, Sinclair E, Landay AL, Lurain N, Sharrett AR, Gange SJ, et al. T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis 2011 203452-463.
25. Breton G, Chomont N, Takata H, Fromentin R, Ahlers J, Filali-Mouhim A, et al. Programmed death-1 is a marker for abnormal distribution of naive/memory T cell subsets in HIV-1 infection. J Immunol 2013 1912194-2204.
26. Sauce D, Almeida JR, Larsen M, Haro L, Autran B, Freeman GJ, et al. PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status. AIDS 2007 212005-2013.
27. Zhang JY, Zhang Z, Wang X, Fu JL, Yao J, Jiao Y, et al. PD-1 upregulation is correlated with HIV-specific memory CD8R Tcell exhaustion in typical progressors but not in long-term nonprogressors. Blood 2007 1094671-4678.
28. Grabmeier-Pfistershammer K, Steinberger P, Rieger A, Leitner J, Kohrgruber N. Identification of PD-1 as a unique marker for failing immune reconstitution in HIV-1-infected patients on treatment. J Acquir Immune Defic Syndr 2011 56118-124.
29. Hatano H, Jain V, Hunt PW, Lee TH, Sinclair E, Do TD, et al. Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4R T cells. J Infect Dis 2013 20850-56.
30. Catalfamo M, Di Mascio M, Hu Z, Srinivasula S, Thaker V, Adelsberger J, et al. HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proc Natl Acad Sci USA 2008 10519851-19856.
31. Catalfamo M, Wilhelm C, Tcheung L, Proschan M, Friesen T, Park JH, et al. CD4 and CD8 T cell immune activation during chronic HIV infection roles of homeostasis, HIV, type I IFN, and IL-7. J Immunol 2011 1862106-2116.
32. Napolitano LA, Grant RM, Deeks SG, Schmidt D, De Rosa SC, Herzenberg LA, et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion implications for T-cell homeostasis. Nat Med 2001 773-79.
33. Kinter AL, Godbout EJ, McNally JP, Sereti I, Roby GA, O'Shea MA, et al. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 2008 1816738-6746.
34. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006 121365-1371.
35. Naeger DM, Martin JN, Sinclair E, Hunt PW, Bangsberg DR, Hecht F, et al. Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One 2010 5e8886.